In various randomized phase III clinical trials, EGFR and ALK TKIs have always shown higher efficacy than chemotherapy, making targeted therapy the standard treatment for advanced NSCLC with such gene mutations (53, 54). The gene discussed is ALK; the disease is non-small cell lung carcinoma.